Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades
-
Published:2023-04-19
Issue:4
Volume:11
Page:1218
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Nagy Nikolett1, Papp Gábor1ORCID, Gáspár-Kiss Eszter1, Diószegi Ágnes2, Tarr Tünde1
Affiliation:
1. Division of Clinical Immunology, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary 2. Division of Metabolic Disorders, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
Abstract
Systemic lupus erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which potentially results in a more severe disease course and reduced life expectancy. Since the therapeutic guidelines have been refined in the last 15 years, we assumed that the diseases course has become more favorable. In order to shed light on these achievements, we compared the data of SLE patients diagnosed before and since 2004. In our retrospective study, we assessed a wide spectrum of clinical and laboratory data of 554 SLE patients who received regular follow-up care and therapy at our autoimmune center. Among these patients, 247 had antiphospholipid antibodies (APAs) without clinical signs of APS, and 113 had definitive APS. In the APS group, among patients diagnosed since 2004, deep vein thrombosis (p = 0.049) and lupus anticoagulant positivity (p = 0.045) were more frequent, while acute myocardial infarction was less frequent (p = 0.021) compared with patients diagnosed before 2004. Among the APA positive patients without definitive APS, anti-cardiolipin antibody positivity (p = 0.024) and development of chronic renal failure (p = 0.005) decreased in patients diagnosed since 2004. Our study demonstrates that the disease course has changed in recent years; however, in the presence of APS, we have to expect repeated thrombotic events despite adequate anticoagulant therapy.
Funder
National Research, Development and Innovation Office
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference33 articles.
1. Cervera, R., Espinosa, G., and Khamashta, M. (2017). Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Elsevier. [2nd ed.]. 2. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective from The Blood Coagulation System;Clin. Appl. Thromb. Hemost.,2022 3. Alijotas-Reig, J., Esteve-Valverde, E., Anunciación-Llunell, A., Marques-Soares, J., Pardos-Gea, J., and Miró-Mur, F. (2022). Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J. Clin. Med., 11. 4. Chronic high-dose glucocorticoid therapy triggers the development of chronic organ damage and worsens disease outcome in systemic lupus erythematosus;Tarr;Clin. Rheumatol.,2017 5. Szabó, K., Jámbor, I., Pázmándi, K., Nagy, N., Papp, G., and Tarr, T. (2022). Altered circulating follicular T helper cell subsets and follicular T regulatory cells are indicators of a derailed B cell response in lupus, which could be modified by targeting IL-21R. Int. J. Mol. Sci., 23.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|